资讯

Moderna 首席执行官 Stéphane Bancel 在新闻稿中表示:“FDA 批准我们的第二款 [RSV] 产品 mRESVIA,这建立在我们 mRNA 平台的优势和多功能性之上。”“mRESVIA 可保护老年人免受 RSV 感染的严重后果,它是唯一一种采用预填充注射器的 RSV 疫苗,旨在最大限度地提高给药的便利性,节省接种者的时间并降低管理错误的风险。” ...
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...
A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...
Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
Moderna Inc. (NASDAQ: MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...
Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.
Moderna 的季节性流感 mRNA 疫苗 mRNA-1010 在 III 期试验中展现出显著优势 —— 在 50 岁及以上人群中,其预防流感的效果比现有标准剂量疫苗高出 26.6%。这项覆盖 11 个国家、超 4 万名受试者的研究显示,65 岁以上老年人群的保护效力提升更为明显,达 27.4%。细分病毒株数据进一步验证其优势:对 A/H1N1 株保护效力提高 29.6%,A/H3N2 株提高 ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease ...